An experienced executive leader with 25+ years in a wide variety of life sciences area’s: CRO, Pharmaceutical, Biotech, Functional Food, Diagnostics and Medical Devices.
Key leadership roles as (Interim) CEO, CCO and (Senior) Vice President in account, line, marketing, scientific and operational management for local and global companies.
Success is driven by focus, commitment, getting it done and an intrinsic motivation to increase people’s personal performance.
Member of several Executive Steering Committees, both for large global pharma as biotech companies in Europe and USA. Has secured over $1.5 billion in investments and opportunities.
Managed Phase I-IIa clinics in The Netherlands with successful delivery of appr. 250 phase I & II trials. Leading role in international mergers and acquisitions, including organizational integration. Currently CEO of Biotech and Diagnostic start-ups and adviser to PE/VC.
A Clinical Research Professional (Pharmacist), PhD (Medical School – Pharmacology/Toxicology) and PMP (2016) with more than 20 years’ experience in Biotech / Health Care Industry / CRO / Drug Development / Clinical Research.
Expertise ranging from Clinical Research/Clinical Operations experience in Pharma, Biotech and CRO with focus on Oncology, Immunology, Infectious Disease, Respiratory indications and Rare/Orphan indications.
Focused on goal achievement, constant striving for improving processes on an international / global level, strong project management background.
Dedication to people management as the main success factor in clinical research/clinical development – foster open & trustful communication on a global level.
Strong believer in “Manage by example” as key to success in drug development
Starting in the Clinical Research area 30 years ago as a study coordinator I have worked my way to being senior director of clinical operations of AM-Pharma through roles in clinical Pharmacology, different CNS areas in midsize Pharma. CNS, Leukemia and now Acute Kidney Injury in Biotech companies. The Biotech has really stolen my heart and sole because of the creativity you have to use in these small companies and the close cooperation with every department. Regulatory Inspections are not a threat but I actually have to say I like them. Partially because I like to be challenged but also because I believe you can constantly work towards a good outcome. There are always findings but they are also a recipe for improvement.
Tanja holds a PhD in Neurosciences from the University of Montreal. She then moved to Paris to persue her research on metalloproteases as drug targets in academia before joining Pharmaleads in 2006 as Head of Biochemistry, characterizing metalloprotease and inhibitor activity in vitro and in vivo, through the design of specific assays. Her work was essential in selecting Pharmaleads’ drug candidates, Dual development in the treatment of severe pain.
In 2014, Tanja was appointed Head of Clinical Operations overseeing all operational aspects of the DENKIs clinical trials and was names Director of Clinical Development in 2017.
Pharma & biotech professional with 16 years’ experience in clinical trial set-up, monitoring, management and in program leadership. My work experience to date includes a number of indications including oncology, paediatric rare diseases, cardiovascular disease, CNS and rheumatology across all phases in small, medium and large biotechnology and pharmaceutical companies. I am experienced in vendor, budget and matrix project team management and possess a sound understanding of the drug development process gained both professionally and academically.
Originally graduated as a Pharmacist in Madrid, and later completed my academic education with an MBA and a Master in Public Health from Liverpool University.
Over 25 years of international experience within the pharmaceutical industry in Regulatory Affairs, Medical Affairs, Marketing, Scientific Communications and Clinical Operations in global and local positions in areas from cardiovascular to oncological diseases.
In the last 2 years my main professional interest has shifted towards Patient centricity within clinical development, recently taking on new responsibilities as R& D Chief Patient Officer.
My current responsibility is the incorporation of patients´ voice across the research and development process of new medicines. This covers the development and coordination of project and study patient centric plans, identification of best-practises and development of KPIs in a cross-traversal manner with patients partners and internal stakeholders.
A 15-year veteran of the translation industry with a background in linguistics, Kathleen has held various roles in the translation business: vendor, project and account management, as well as new business development. Her experiences have positioned her with a unique perspective into both translation operations and how translation impacts the globalization needs of clients in the pharmaceutical and medical device industries. Kathleen proactively collaborates with her Life Sciences client partners on a daily basis to help them set their localization strategies.
With more than 25 years of experience in the Life Sciences industry, David is a seasoned executive with extensive experience delivering solutions to customers, with a particular focus in the areas of regulatory information management (RIM), content management and collaboration. His main focus is aligning customer needs with the capabilities of the company’s Life Sciences Suite and ensure that the solution meets the needs of the customer. David also leads the DIA EDM Submission Reference Model team that developed a document architecture for use when designing and building content management solutions.
